Clinical trial · Interventional
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Decision to stop development of AZD1480
Summary
Brief summary (as posted)
This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD1480 | Drug | JAK2 Inhibitor AZD1480 | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- AZD1480 until Maximum Tolerated Dose (MTD) is reached
- interventionNames
- Drug: AZD1480
- type
- EXPERIMENTAL
- label
- 2
- description
- AZD1480 dose expansion of MTD
- interventionNames
- Drug: AZD1480
Primary outcomes (1)
- measure
- Safety and tolerability as assessed by Adverse events, vital signs, ECGs, Pulmonary Function Tests (DLco, FEV, FVC, Oxygen saturation) and laboratory data (chemistry, hematology and Urinalysis)
- timeFrame
- Information will be collected from the time the informed consent is signed, throughout the study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced solid cancer without available therapy in the escalation phase and mutation positive NSCLC or non-smokers with other primary tumors lung metastasis in the expansion phase * ECOG Performance Status 0-1 * Evidence of post-menopausal status in females or males willing to use barrier contraception Exclusion Criteria: * Prior therapy with any JAK2 medications * Significant lung disorder or lung disease. Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 21 days before study screening. Evidence of significant pulmonary hypertension or COPD * Eye disease of the cornea
References
Publications (0)
Data not yet available